Colony-stimulating factor 3 and its receptor promote leukocyte immunoglobulin-like receptor B2 expression and ligands in gastric cancer

Figures

• 

  Figure 1. Analysis of differentially expressed genes between patients with high and low colony-stimulating factor 3 receptor expression. A: Volcano plots of differentially expressed genes (DEGs); B: Heatmap of DEGs; C: Enrichment analysis of DEGs by Kyoto Encyclopedia of Genes and Genomes; D: Enrichment analysis of DEGs by Gene Ontology.

• 

  Figure 2. Immune checkpoints showing the most significant differences between high and low colony-stimulating factor 3 expression groups. A: Leukocyte immunoglobulin-like receptor B2; B: Hepatitis A virus cellular receptor 2; C: Chemokine receptor 2; D: CD80; E: Inducible T-cell costimulator; F: CD28. dP < 0.0001.

• 

  Figure 3. Immunohistochemical staining of gastric cancer tissues (200 ×). A: Leukocyte immunoglobulin-like receptor B2 (high expression); B: Angiopoietin-like protein 2 (high expression); C: Human leukocyte antigen-G (high expression); D: Colony-stimulating factor 3 receptor (high expression); E: Leukocyte immunoglobulin-like receptor B2 (low expression); F: Angiopoietin-like protein 2 (low expression); G: Human leukocyte antigen-G (low expression); H: Colony-stimulating factor 3 receptor (low expression).

• 

  Figure 4. Correlation of mRNA expression. A-F: Correlation of mRNA expression levels between colony-stimulating factor 3 receptor, leukocyte immunoglobulin-like receptor B2, angiopoietin-like protein 2, and human leukocyte antigen-G. CSF3R: Colony-stimulating factor 3 receptor; LILRB2: Leukocyte immunoglobulin-like receptor B2; ANGPTL2: Angiopoietin-like protein 2; HLA-G: Human leukocyte antigen-G.

• 

  Figure 5. The mRNA expression of leukocyte immunoglobulin-like receptor B2, angiopoietin-like protein 2, and human leukocyte antigen-G. A-C: The mRNA expression levels at different time points; D-F: The mRNA expression levels at different time points after administration of colony-stimulating factor 3 compared with control groups. aP < 0.001; bP < 0.01; cP < 0.05. LILRB2: Leukocyte immunoglobulin-like receptor B2; ANGPTL2: Angiopoietin-like protein 2; HLA-G: Human leukocyte antigen-G; CSF3: Colony-stimulating factor 3; NC: Negative control.

• 

  Figure 6. Protein expression of leukocyte immunoglobulin-like receptor B2, angiopoietin-like protein 2, and human leukocyte antigen-G at different time points after administration of colony-stimulating factor 3 compared with control groups. A-C: Protein expression levels at different time points. D: Protein expression at different time points. aP < 0.001; cP < 0.05. LILRB2: Leukocyte immunoglobulin-like receptor B2; ANGPTL2: Angiopoietin-like protein 2; HLA-G: Human leukocyte antigen-G; CSF3: Colony-stimulating factor 3.

• 

  Figure 7. Colony-stimulating factor/colony-stimulating factor 3 receptor regulates the expression of leukocyte immunoglobulin-like receptor B2, angiopoietin-like protein 2, and human leukocyte antigen-G through heterogeneous nuclear ribonucleoprotein H1. A-C: The mRNA expression levels when heterogeneous nuclear ribonucleoprotein H1 (hnRNPH1) expression is downregulated or upregulated; D: Protein expression levels when hnRNPH1 expression is downregulated or upregulated; E-G: The mRNA expression levels when hnRNPH1 expression is downregulated with or without colony-stimulating factor 3 stimulation; H: Protein expression levels when hnRNPH1 expression is downregulated with or without colony-stimulating factor 3 stimulation. aP < 0.0001; bP < 0.001; cP < 0.01; dP < 0.05. LILRB2: Leukocyte immunoglobulin-like receptor B2; ANGPTL2: Angiopoietin-like protein 2; HLA-G: Human leukocyte antigen-G; hnRNPH1: heterogeneous nuclear ribonucleoprotein H1; CSF3R: Colony-stimulating factor 3 receptor.